3Van de Weyer, C (2005) Changing Diets, Changing Minds: How Food Affects Mental Well Being and Behaviour. London: Sustain.
4Fernstrom, JD (1990) Aromatic amino acids and monoamine synthesis in the central nervous system: influence of the diet. J Nutr Biochem 1, 508–517.
5Wurtman, RJ & Fernstrom, JD (1975) Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr 28, 638–647.
6Frederick, AL & Stanwood, GD (2009) Drugs, biogenic amine targets and the developing brain. Dev Neurosci 31, 7–22.
7Jayanthi, LD & Ramamoorthy, S (2005) Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J 7, E728–E738.
8Lucki, I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44, 151–162.
9Missale, C, Nash, SR, Robinson, SW, et al. (1998) Dopamine receptors: from structure to function. Physiol Rev 78, 189–225.
10Haskell, CF, Scholey, AB, Jackson, PA, et al. (2008) Cognitive and mood effects in healthy children during 12 weeks' supplementation with multi-vitamin/minerals. Br J Nutr 100, 1086–1096.
11Kennedy, DO, Scholey, AB, Tildesley, NT, et al. (2002) Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav 72, 953–964.
12Tildesley, NT, Kennedy, DO, Perry, EK, et al. (2005) Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav 83, 699–709.
13Tildesley, NT, Kennedy, DO, Perry, EK, et al. (2003) Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 75, 669–674.
14Scholey, AB, Tildesley, NT, Ballard, CG, et al. (2008) An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berlin) 198, 127–139.
15Ofir, R, Tamir, S, Khatib, S, et al. (2003) Inhibition of serotonin re-uptake by licorice constituents. J Mol Neurosci 20, 135–140.
16Yáñez, M, Fraiz, N, Cano, E, et al. (2006) Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 344, 688–695.
17Dhingra, D & Sharma, A (2006) Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog Neuropsychopharmacol Biol Psychiatry 30, 449–454.
18Dhingra, D, Parle, M & Kulkarni, SK (2004) Memory enhancing activity of Glycyrrhiza glabra in mice. J Ethnopharmacol 91, 361–365.
19de Moraes Pultrini, A, Galindo, LA & Costa, M (2006) Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in mice. Life Sci 78, 1720–1725.
20Bergström, LS & Lynöe, N (2008) Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scand J Public Health 36, 532–537.
21Fowler, A, Seifert, N, Acker, V, et al. (2006) A nonradioactive high-throughput/high-content assay for measurement of the human serotonin reuptake transporter function in vitro. J Biomol Screen 11, 1027–1034.
22Qian, Y, Galli, A, Ramamoorthy, S, et al. (1997) Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 17, 45–57.
23Holt, A, Sharman, DF, Baker, GB, et al. (1997) A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 244, 384–392.
24White, HL, Scates, PW & Cooper, BR (1996) Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 58, 1315–1321.
25Yamada, M & Yasuhara, H (2004) Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 25, 215–221.
26Lucki, I, Dalvi, A & Mayorga, AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155, 315–322.
27Porsolt, RD, Bertin, A & Jalfre, M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229, 327–336.
28Njung'e, K & Handley, SL (1991) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38, 63–67.
29Njung'e, K & Handley, SL (1991) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104, 105–112.
30Londei, T, Valentini, AMV & Leone, VG (1998) Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 94, 249–254.
31Broekkamp, CL, Rijk, HW, Joly-Gelouin, D, et al. (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126, 223–229.
32Crawley, JN (1981) Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15, 695–699.
33Kreiss, DS, Wieland, S & Lucki, I (1993) The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience 52, 295–301.
34Malagié, I, Trillat, AC, Jacquot, C, et al. (1995) Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol 286, 213–217.
35Felton, TM, Kang, TB, Hjorth, S, et al. (2003) Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367, 297–305.
36Maione, S, Palazzo, E, Pallotta, M, et al. (1997) Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat. Psychopharmacology (Berl) 134, 401–405.
37Rutter, JJ & Auerbach, SB (1993) Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 265, 1319–1324.
38Paxinos, G & Watson, C (1986) The Rat Brain in Stereotaxic Coordinates. London: Academic Press.
39Carlier, PR, Lo, MM, Lo, PC, et al. (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett 8, 487–492.
40Skolnick, P, Popik, P, Janowsky, A, et al. (2003) Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor. Eur J Pharmacol 461, 99–104.
41Skolnick, P, Popik, P, Janowsky, A, et al. (2003) “Broad spectrum” antidepressants: is more better for the treatment of depression? Life Sci 73, 3175–3179.
42Nutt, DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69, Suppl. E1, 4–7.
43Cryan, JF, Valentino, RJ & Lucki, I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29, 547–569.
44Sillaber, I, Panhuysen, M, Henniger, MS, et al. (2008) Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 200, 557–572.
45Hirano, K, Kimura, R, Sugimoto, Y, et al. (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144, 695–702.
46Hascoët, M, Bourin, M & Nic Dhonnchadha, BA (2000) The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav 67, 45–53.
47Bourin, M, Redrobe, JP, Hascoët, M, et al. (1996) A schematic representation of the psychopharmacological profile of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 20, 1389–1402.
48Mason, SS, Baker, KB, Davis, KW, et al. (2009) Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. Eur J Pharmacol 602, 306–315.
49Kulkarni, SK & Dhir, A (2007) Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry 31, 1248–1254.
50Nicolas, LB, Kolb, Y & Prinssen, EP (2006) A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 547, 106–115.
51Kobayashi, T, Hayashi, E, Shimamura, M, et al. (2008) Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 197, 567–580.
52Li, X, Morrow, D & Witkin, JM (2006) Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78, 1933–1939.
53Bourin, M & Hascoët, M (2003) The mouse light/dark box test. Eur J Pharmacol 463, 55–65.
54Melo, FHC, Venâncio, ET, de Sousa, DP, et al. (2010) Anxiolytic-like effect of carvacrol (5-isopropyl-2-methylphenol) in mice: involvement with GABAergic transmission. Fundam Clin Pharmacol 24, 437–443.
55Machado, DG, Bettio, LE, Cunha, MP, et al. (2009) Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 33, 642–650.